Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Detailed information in session information below
Professor Giuseppe Rosano, FESC, FHFASt George's Hospital Medical SchoolLondon, United Kingdom
Professor Petar Seferovic, FESC, FHFABelgrade University School of MedicineBelgrade, Serbia
Professor Andrew Coats, FESC, FHFAUniversity of WarwickCoventry, United Kingdom
This webinar addresses general cardiologists but also cardiologists wishing to update their scientific knowledge on the topic.
During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.
An application has been made to the EACCME® for CME accreditation of this event.
Type 2 diabetes mellitus and heart failure (HF) are both common, frequently co-exist and have a strong impact on clinical management and prognosis. Diabetes is associated with worse outcomes in both patients with HF with reduced and preserved ejection fraction, in comparison to HF patients without diabetes.
Also, reduced ejection fraction is an independent predictor of fatal and non-fatal clinical outcomes in patients with diabetes. Treatment of diabetic patients with HF can be challenging for adverse effects of these drugs. There has been uncertainty about the safety of older antidabetic drugs such as insulin and sulphonlyureas in patients with diabetes and HF but there are no randomized trials to allow firm conclusions.
In patients with diabetes without HF, some drugs have been shown to increase the risk of HF hospitalizations (i.e. rosiglitazone, pioglitazone and saxagliptin) and, therefore they are contraindicated in patients diabetes with prior HF or at risk of HF. Large clinical trials investigating safety of newer antidiabetic drugs in patients with CV disease or at high CV risk have demonstrated that GLP-1 receptor agonists and a DPP4 inhibitor, sitagliptin, have a neutral effect on the risk of HF hospitalisations. In addition, SGLT2 inhibitors, empagliflozin and canagliflozin demonstrated a significant reduction in the risk of HF hospitalizations in patients with diabetes.
Taking all into account, this Webinar will add to knowledge of troublesome treatment of diabetes in HF patients. The attendees will be updated on the new modalities for diagnosing and treating diabetic patients with chronic heart failure according to the 2016 ESC/HFA Heart Failure Guidelines.
In addition, they will learn when and how to use the new anti-diabetic medications in diabetic patients with heart failure.
Furthermore, they will be updated on the optimal management of diabetes mellitus, including appropriate HbA1c targets, when to treat patients with heart failure or at increased risk of heart failure.
Finally, new therapeutic algorithm for diabetic patients with diabetes mellitus and arterial hypertension at increased risk of heart failure will be also presented.
The webinar is available on PC and tablets. The use of a smartphone is not recommended.
To answer the MCQs during the live, you must allow pop-up windows.
A high-speed Internet connection is required (minimum 2 Mbps).
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903, Sophia Antipolis, FR
This programme is supported by AstraZeneca in the form of an educational grant.
The scientific programme has not been influenced in any way by its sponsor.
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.